AbbVie's immunology franchise is firing on all cylinders while Bristol Myers Squibb navigates revenue declines and legal ...
Zacks Investment Research on MSN
Are medical stocks lagging Bristol Myers Squibb (BMY) this year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Bristol Myers Squibb (BMY) been one of those stocks this year ...
Bristol-Myers Squibb stock closed at USD 62.84 on the NYSE on September 17, 2026, about 8.4% below its 52-week high after a ...
As management tackles key issues head-on, Bristol Myers Squibb stock offers a steady 4% yield, with further upside potential.
Bristol-Myers Squibb (NYSE:BMY) is funding lung cancer screening research in India that targets risks beyond smoking. The ...
Bristol Myers Squibb (BMY) closed the most recent trading day at $62.84, moving 1.19% from the previous trading session.
Bristol Myers Squibb's aggressive M&A and in-house R&D efforts have driven the portfolio renewal cadence and ongoing ...
Bristol Myers Squibb remains significantly undervalued, trading at a forward P/E of 8x, versus the sector median of 19.5x. BMY's growth portfolio now generates 57% of total revenue, growing 18% YoY ...
Bristol-Myers Squibb stock (ISIN US1078421011) is trading close to USD 63.60 on the New York Stock Exchange as of September ...
Bristol Myers Squibb Co. BMY on Thursday shared long-term results from the Phase 3 POETYK PsA-2 trial and its open-label ...
On 8, 2026, Bristol-Myer’s Squibb filed BPCIA Case No. 1:26-cv-01134 (D. Del.) against Amgen’s proposed Opdivo® (nivolumab) biosimilar ...
Arlo-cel uses autologous T-cell collection, ex vivo CAR engineering, lymphodepletion, and single infusion, necessitating infrastructure for manufacturing logistics and post-infusion monitoring. Safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results